Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Bayer Obtains Approval for Eylea for Macular Edema Secondary to Retinal Vein Occlusion
June 30, 2015
- Study for Myelodysplastic Syndrome in Japan: SymBio
June 30, 2015
- Takeda Chairman Hasegawa Gives Up Representative Rights
June 29, 2015
- Aspen Japan Takes Over Decadron from MSD
June 29, 2015
- UCB Japan Applies for Approval of Antiepileptic Agent Lacosamide in Japan
June 29, 2015
- RaQualia Regains Domestic Rights to Dalbavancin from Allergan
June 29, 2015
- Lixiana Gets EU Regulatory Approval: Daiichi Sankyo
June 26, 2015
- EU OKs Fycompa as Adjunct Therapy for PGTC Seizures: Eisai
June 26, 2015
- Sosei Group “Not in Hurry” to License Out Compounds Obtained through Heptares Acquisition: President Tamura
June 26, 2015
- Naldemedine Meets Primary, Secondary Endpoints in Japanese PIII Study for the Treatment of OIC in Cancer Patients: Shionogi
June 26, 2015
- Novartis Seeks Japan Approval of Ceritinib
June 25, 2015
- Takeda CFO Roger to Resign in under 2 Years
June 25, 2015
- Japan Vaccine Studying Marketing Strategy for 3 Seasonal Flu Vaccines, Marketing System for Adult Vaccines as Well
June 24, 2015
- AnGes MG Grants MTPC Marketing Rights for HGF Gene Treatment for Peripheral Vascular Diseases in Japan
June 24, 2015
- Hemophilia A Treatment Candidate to Move to PIII During 2015 Based on Favorable Results in PI/II Studies: Chugai
June 24, 2015
- Lilly Japan Oncology Chief Hopeful on Cyramza Growth
June 23, 2015
- Favorable PIII Data Out for Nichi-Iko’s Remicade Biosimilar
June 23, 2015
- Biogen Idec Japan Rebranded as Biogen Japan
June 23, 2015
- Opdivo Wins European Approval for Advanced Malignant Melanoma: BMS
June 23, 2015
- Fycompa Approved as Adjunctive Treatment for Primary Generalized Tonic-Clonic Seizures in US: Eisai
June 23, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…